Comparison of the QIAGEN artus HBV QS-RGQ Assay With the Roche COBAS AmpliPrep/COBAS TaqMan HBV Assay for Quantifying Viral DNA in Sera of Chronic Hepatitis B Patients
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Hepatitis B virus DNA quantification is essential for managing chronic hepatitis B (CHB). We compared the performance of artus HBV QS-RGQ (QIAGEN GmbH, Germany) and CAP/CTM v2.0 HBV assays (Roche Molecular Diagnostics, USA) in CHB patients. Methods: A comparative evaluation between two assays was performed with 508 clinical serum samples. Precision, linearity, and the limit of detection (LOD) of QS-RGQ assay was evaluated by using the WHO standard 97/750 and clinical samples. Results: Detection rates and viral loads as determined QS-RGQ assay were significantly lower than those from the CAP/CTM v2.0 assay (52.8% vs 60.6%; 3.55±1.77 IU/mL vs 4.18±1.89 IU/mL, P<0.0001). The kappa coefficient between qualitative results was 0.79 (95% confidence interval, 0.74 to 0.85). Bland-Altman plot found a mean difference of (QS-RGQ - CAP/CTM v2.0)=–0.63 log10 IU/mL (95% limit of agreement, –1.48 to 0.22). Repeatability and total imprecision (% CV) of the QS-RGQ assay were 1.0% and 1.1% at 2,000 IU/mL, and 0.7% and 1.4% at 20,000 IU/mL, respectively. Linearity of this assay ranged from 31.6 to 1.0±107 IU/mL, and the LOD was 2.95 IU/mL. Conclusions: The artus HBV QS-RGQ assay showed good performance but significantly decreased detection rate and viral load compared with CAP/CTM v2.0 assays. This assay recommends using plasma; however, we used stored serum because of the retrospective study design. Usually HBV DNA quantification is performed in plasma or serum, but sample type and clinical relevance of quantitative values should be considered when determining the clinical application of this reagent.
Abstract
Background: Hepatitis B virus DNA quantification is essential for managing chronic hepatitis B (CHB). We compared the performance of artus HBV QS-RGQ (QIAGEN GmbH, Germany) and CAP/CTM v2.0 HBV assays (Roche Molecular Diagnostics, USA) in CHB patients. Methods: A comparative evaluation between two assays was performed with 508 clinical serum samples. Precision, linearity, and the limit of detection (LOD) of QS-RGQ assay was evaluated by using the WHO standard 97/750 and clinical samples. Results: Detection rates and viral loads as determined QS-RGQ assay were significantly lower than those from the CAP/CTM v2.0 assay (52.8% vs 60.6%; 3.55±1.77 IU/mL vs 4.18±1.89 IU/mL, P<0.0001). The kappa coefficient between qualitative results was 0.79 (95% confidence interval, 0.74 to 0.85). Bland-Altman plot found a mean difference of (QS-RGQ - CAP/CTM v2.0)=–0.63 log10 IU/mL (95% limit of agreement, –1.48 to 0.22). Repeatability and total imprecision (% CV) of the QS-RGQ assay were 1.0% and 1.1% at 2,000 IU/mL, and 0.7% and 1.4% at 20,000 IU/mL, respectively. Linearity of this assay ranged from 31.6 to 1.0±107 IU/mL, and the LOD was 2.95 IU/mL. Conclusions: The artus HBV QS-RGQ assay showed good performance but significantly decreased detection rate and viral load compared with CAP/CTM v2.0 assays. This assay recommends using plasma; however, we used stored serum because of the retrospective study design. Usually HBV DNA quantification is performed in plasma or serum, but sample type and clinical relevance of quantitative values should be considered when determining the clinical application of this reagent.
참고문헌 (21)
- "Hepatitis B"[URL]
- Oakes K, "Hepatitis B : prevalence and pathophysiology", Nurs Times, 110, pp.12~16 (2014)
- Lok AS, "Chronic hepatitis B: update 2009", Hepatology, 50, pp.661~662 (2009)
- Martin P, "A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2015 Update", Clin Gastroenterol Hepatol, 13, pp.2071~2087 (2015)
- González R, "Efficacy of hepatitis B virus (HBV) DNA screening and characterization of acute and occult HBV infections among blood donors from Madrid, Spain", Transfusion, 50, pp.221~230 (2010)
- Jiang JN, "Residual amount of HBV DNA in serum is related to relapse in chronic hepatitis B patients after cessation of nucleos(t)ide analogs", J Clin Gastroenterol, 49, pp.323~328 (2015)
- Stelzl E, "Rapid quantification of hepatitis B virus DNA by automated sample preparation and real-time PCR", J Clin Microbiol, 42, pp.2445~2449 (2004)
- Poljak M, "Recent developments in serologic and molecular diagnosis of hepatitis B and C", Acta medica Croatica, 67, pp.281~290 (2013)
- Ismail AM, "Performance characteristics and comparison of Abbott and artus real-time systems for hepatitis B virus DNA quantification", J Clin Microbiol, 49, pp.3215~3221 (2011)
- Yeh ML, "Comparison of the Abbott RealTime HBV assay with the Roche Cobas AmpliPrep", Cobas TaqMan HBV assay for HBV DNA detection and quantification, 2014, pp.60, 206~214
- Brichler S, "P0543: Comparative evaluation of the artus HBV QS-RGQ assay and the roche cobas mpliprep", cobas taqman V.2 HBV test for the quantification of HBV DNA in plasma, 2015, pp.62, S518~S519
- Fielder H, "Quantitative detection of hepatitis B virus (HBV) DNA with the novel artus® HBV QS-RGQ Kit version 2", J Clin Virol, 70, pp.S85~ (2015)
- Allice T, "COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma", J Clin Microbiol, 45, pp.828~834 (2007)
- Chevaliez S, "Performance of version 2.0 of the Cobas AmpliPrep", Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification, 2010, pp.48, 3641~3647
- Caliendo AM, "Multilaboratory evaluation of real-time PCR tests for hepatitis B virus DNA quantification", J Clin Microbiol, 49, pp.2854~2858 (2011)
- Lok AS, "Natural history and control of perinatally acquired hepatitis B virus infection", Dig Dis, 10, pp.46~52 (1992)
- Funk ML, "World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants", J Viral Hepat, 9, pp.52~61 (2002)
- Lindh M, "Lamivudine resistance of hepatitis B virus masked by coemergence of mutations in probe region of the COBAS AMPLICOR assay", J Clin Microbiol, 44, pp.2587~2589 (2006)
- Yeh ML, "Abbott RealTime HBV assay is more sensitive in detection of low viral load and little impacted by drug resistant mutation in chronic hepatitis B patients under nucleot(s)ide analogues therapy", PLoS One, 9, pp.e101790~ (2014)
- Alestig E, "Phylogenetic origin of hepatitis B virus strains with precore C-1858 variant", J Clin Microbiol, 39, pp.3200~3203 (2001)
- Alexopoulou A, "HBeAg negative variants and their role in the natural history of chronic hepatitis B virus infection", World J Gastroenterol, 20, pp.7644~7652 (2014)